We further tested this hypothesis in patients who were diagnosed with advanced EGFR-mutated NSCLC and treated with EGFR-TKIs by monitoring early dynamic changes of resistance-associated gene alterations during treatment using plasma circulating tumor DNA (ctDNA). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.